BioMarin Pharmaceuticals (BMRN)

• Market cap: $11B
• 1 day: -1.85%
• 5 days: -1.33%
• 1 month: 3.71%
• 3 months: -2.32%
• 6 months: -8.38%
• Year to date: -13.84%
• 1 year: -31.26%
• 5 years: -56.28%
• 10 years: -61.58%
• Sector: Healthcare
• Industry: Biotechnology

About: BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.

Employees: 3,040

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

85% more first-time investments, than exits

New positions opened: 102 | Existing positions closed: 55

39% more repeat investments, than reductions

Existing positions increased: 239 | Existing positions reduced: 172

11% more call options, than puts

Call options by funds: $97.7M | Put options by funds: $87.7M

8% more funds holding

Funds holding: 534 [Q4 2024] → 576 (+42) [Q1 2025]

7% more capital invested

Capital invested by funds: $12B [Q4 2024] → $12.8B (+$783M) [Q1 2025]

0.35% less ownership

Funds ownership: 96.11% [Q4 2024] → 95.76% (-0.35%) [Q1 2025]

14% less funds holding in top 10

Funds holding in top 10: 7 [Q4 2024] → 6 (-1) [Q1 2025]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $78 36% upside
• Avg. target: $98 72% upside
• High target: $113 97% upside

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

JP Morgan Jessica Fye	97% upside $113	Overweight Maintained	14 Jul 2025
Goldman Sachs Salveen Richter	82% upside $104	Buy Maintained	5 May 2025
Citigroup David Lebovitz	36% upside $78	Neutral Maintained	2 May 2025